Beckman Coulter Debuts Hematology Analyzer and Slidemaker Stainer Connected to Scopio Labs’ Digital Morphology Platform

By LabMedica International staff writers
Posted on 21 Jul 2023

Image: The Scopio X100HT digital morphology platform is capable of continuous loading, scanning and analysis (Photo courtesy of Beckman Coulter)

Beckman Coulter, Inc. (Brea, CA, USA) is launching its hematology analyzer and slidemaker stainer connected to Scopio Labs’ (Tel Aviv, Israel) digital morphology platform for end-to-end digitization with artificial intelligence-assisted peripheral blood smear analysis at the 2023 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo. The solution features the Beckman Coulter DxH 900 Workcell and DxH Slidemaker Stainer II connected with the Scopio X100HT digital morphology platform capable of continuous loading, scanning, and analysis.

In manual microscopy, users must choose between a large field of view or high resolution. Scopio solves that trade-off, capturing large scan areas at 100X magnification, and virtually eliminates the need for additional manual microscopic examination. With this newly connected capability, the X100HT is able to process up to 30 samples an hour, meeting the high-throughput requirements of large hospitals and labs, and fully supports remote review capabilities. In 2022, Scopio Labs received U.S. Food and Drug Administration 510(k) clearance of its X100HT device with its PBS Application coupling high-throughput capabilities with high-resolution scanning for hematological analysis. Catering to large medical facilities and labs across the world, the X100HT complements the previously-cleared X100 instrument designed with a 3-slide tray and a throughput of up to 15 slides an hour for a 200 WBC Diff, making it an optimal solution for small to medium size laboratories.

At AACC 2023, Beckman Coulter is also exhibiting its new high-throughput DxI 9000 Access immunoassay analyzer that is designed for superior laboratory performance and demands no daily maintenance. The DxI 9000 is the most efficient immunoassay analyzer in terms of footprint, boasting the ability to process up to 215 tests per hour per square meter (tests/hr/m2). The DxI 9000 Analyzer’s cutting-edge features cater to the current demands for speed, reliability, consistency, quality, and menu expansion. Its unique ZeroDaily Maintenance feature further enhances the device's uptime performance, as confirmed by beta users who report that it redefines their workday by eliminating daily maintenance tasks and reducing yearly maintenance routines by up to a staggering 96%. The DxI 9000 Analyzer is equipped with the state-of-the-art PrecisionVision Technology, capable of scrutinizing, identifying, and preventing inaccurate reporting in real-time. Additionally, Beckman Coulter is hosting a workshop to discuss new opportunities for laboratories to reduce QC and operational costs, as well as eliminate unnecessary repeats, recalibrations, and troubleshooting episodes, even in the face of CLIA's tighter standards.

“With the increasing attention of hematological disorders and malignancies, the accuracy and timeliness of peripheral blood smears results are critically important for timely diagnosis and effective treatment initiation,” said Dan Xu, Vice President/GM, Hematology and Urinalysis Business Units for Beckman Coulter. “The peripheral blood smear (PBS) review is a powerful diagnostic tool that provides clinicians with information about a variety of disorders such as blood-related cancers, anemia, infections, and many other life-threatening medical conditions. Often, performing PBS analysis forces medical technicians to compromise on either field of view or resolution and requires physically transferring PBS slides to a microscope for manual review. Our new capability to automatically transfer PBS slides from Beckman Coulter’s DxH Slidemaker Stainer II to the Scopio X100HT platform removes the need for a technician to manually transfer the slides, resulting in lab efficiency for medical technicians, while Scopio’s Full-Field technology removes the need to revert to the microscope for manual review.”

“Connecting the Scopio X100HT with the DxH 900 Workcell is a tremendous step forward in advancing our global partnership with Beckman Coulter, which we initiated one year ago,” said Itai Hayut, CEO and Co-Founder of Scopio Labs. “A fully integrated hematology workflow from the complete blood count (CBC) test to slide staining (SMS) to peripheral blood smears (PBS) will empower qualified experts in detecting blood-related medical conditions.”

Related Links:
Beckman Coulter, Inc.
Scopio Labs